PL2850085T3 - Antywirusowe związki inhibitorowe hcv ns5a - Google Patents

Antywirusowe związki inhibitorowe hcv ns5a

Info

Publication number
PL2850085T3
PL2850085T3 PL13726936T PL13726936T PL2850085T3 PL 2850085 T3 PL2850085 T3 PL 2850085T3 PL 13726936 T PL13726936 T PL 13726936T PL 13726936 T PL13726936 T PL 13726936T PL 2850085 T3 PL2850085 T3 PL 2850085T3
Authority
PL
Poland
Prior art keywords
antiviral compounds
hcv ns5a
compounds inhibitors
inhibitors
ns5a
Prior art date
Application number
PL13726936T
Other languages
English (en)
Polish (pl)
Inventor
John O Link
Jeromy J Cottell
Martin Teresa Alejandra Trejo
Elizabeth M Bacon
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of PL2850085T3 publication Critical patent/PL2850085T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13726936T 2012-05-16 2013-05-15 Antywirusowe związki inhibitorowe hcv ns5a PL2850085T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261647966P 2012-05-16 2012-05-16
US13/831,116 US20130309196A1 (en) 2012-05-16 2013-03-14 Antiviral compounds
EP13726936.1A EP2850085B1 (en) 2012-05-16 2013-05-15 Antiviral compounds inhibitors of hcv ns5a
PCT/US2013/041201 WO2013173488A1 (en) 2012-05-16 2013-05-15 Antiviral compounds inhibitors of hcv ns5b

Publications (1)

Publication Number Publication Date
PL2850085T3 true PL2850085T3 (pl) 2017-10-31

Family

ID=49581469

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13726936T PL2850085T3 (pl) 2012-05-16 2013-05-15 Antywirusowe związki inhibitorowe hcv ns5a
PL17160683T PL3239153T3 (pl) 2012-05-16 2013-05-15 Pochodne 9-(1H-imidazol-5-ilo)-1,11-dihydroizochromeno[4',3':6,7]nafto[1,2-d]imidazolu i ich zastosowanie jako inhibitorów NS5A HCV

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17160683T PL3239153T3 (pl) 2012-05-16 2013-05-15 Pochodne 9-(1H-imidazol-5-ilo)-1,11-dihydroizochromeno[4',3':6,7]nafto[1,2-d]imidazolu i ich zastosowanie jako inhibitorów NS5A HCV

Country Status (19)

Country Link
US (5) US20130309196A1 (h)
EP (2) EP2850085B1 (h)
JP (2) JP6209209B2 (h)
KR (2) KR102078233B1 (h)
CN (3) CN104487442B (h)
AU (3) AU2013262874B2 (h)
BR (1) BR112014028221B1 (h)
CA (1) CA2873485C (h)
EA (2) EA034749B1 (h)
ES (2) ES2738012T3 (h)
HK (1) HK1245262B (h)
IL (1) IL235645A0 (h)
IN (1) IN2014MN02459A (h)
MX (1) MX362060B (h)
PL (2) PL2850085T3 (h)
PT (2) PT3239153T (h)
SG (2) SG11201407533SA (h)
SI (2) SI3239153T1 (h)
WO (1) WO2013173488A1 (h)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1633766T (pt) 2003-05-30 2019-06-04 Gilead Pharmasset Llc Análogos de nucleósido fluorado modificado
KR20180026563A (ko) 2010-11-17 2018-03-12 길리애드 파마셋 엘엘씨 항바이러스 화합물
MX346729B (es) 2011-11-16 2017-03-30 Gilead Pharmasset Llc * Compuestos antivirales.
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
CN105517540B (zh) 2013-08-27 2019-08-23 吉利德制药有限责任公司 两种抗病毒化合物的复方制剂
US20150064252A1 (en) * 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TWI721947B (zh) * 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) * 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
EP3164405A4 (en) 2014-07-02 2018-05-23 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
SMT202100592T1 (it) 2014-12-26 2021-11-12 Univ Emory Derivati antivirali della n4-idrossicitidina
WO2017155844A1 (en) 2016-03-07 2017-09-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US9957279B2 (en) 2016-05-05 2018-05-01 Laurus Labs Limited Process for the preparation of intermediates useful in the preparation of Hepatitis C virus (HCV) inhibitors
CA3025633C (en) 2016-05-27 2021-02-23 Gilead Sciences, Inc. Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
CN108368123B (zh) * 2016-07-08 2021-02-19 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
CN106220639A (zh) * 2016-07-22 2016-12-14 上海众强药业有限公司 一种维帕他韦中间体新晶型
CN110698489B (zh) * 2016-11-30 2022-02-22 上海新礼泰药业有限公司 维帕他韦中间体、制备方法及应用
UY37861A (es) 2017-08-28 2019-03-29 Enanta Pharm Inc Agentes antivirales contra la hepatitis b
CN107501280A (zh) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 一种维帕他韦的合成方法
DK3706762T3 (da) 2017-12-07 2024-12-16 Univ Emory N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil
US11198693B2 (en) 2018-11-21 2021-12-14 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
US20230257348A1 (en) * 2020-08-18 2023-08-17 Merck Sharp & Dohme Llc Cyclopentapyrrole orexin receptor agonists
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN117460734A (zh) * 2021-05-21 2024-01-26 吉利德科学公司 作为寨卡病毒抑制剂的五环衍生物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DE69129650T2 (de) 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Wirkstoffvorläufer von Phosphonaten
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2004235848B2 (en) 2003-05-09 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis C virus NS5B polymerase inhibitor binding pocket
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
HRP20110732T1 (hr) 2004-07-16 2011-11-30 Gilead Sciences Antivirusni spojevi
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
HRP20120440T1 (hr) 2008-02-12 2012-06-30 Bristol-Myers Squibb Company Inhibitori virusa hepatitisa c
AU2008350334B2 (en) 2008-02-13 2013-10-17 Bristol-Myers Squibb Company Imidazolyl biphenyl imidazoles as hepatitis C virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
AU2009322387A1 (en) 2008-12-03 2011-06-30 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
US20120040977A1 (en) * 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
AU2010217797B2 (en) 2009-02-27 2014-02-20 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN102427726B (zh) 2009-03-27 2014-10-08 普雷西迪奥制药公司 丙型肝炎的稠环抑制剂
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
TWI547495B (zh) * 2009-05-13 2016-09-01 吉李德製藥公司 抗病毒化合物
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20120076343A (ko) 2009-09-04 2012-07-09 글락소스미스클라인 엘엘씨 화합물
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
AR080676A1 (es) 2010-03-09 2012-05-02 Schering Corp Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
WO2011146401A1 (en) 2010-05-17 2011-11-24 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011150243A1 (en) * 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2963034A1 (en) 2010-08-26 2016-01-06 RFS Pharma, LLC. Potent and selective inhibitors of hepatitis c virus
US8999967B2 (en) * 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
KR20180026563A (ko) * 2010-11-17 2018-03-12 길리애드 파마셋 엘엘씨 항바이러스 화합물
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
MX346729B (es) * 2011-11-16 2017-03-30 Gilead Pharmasset Llc * Compuestos antivirales.
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
CA2873485A1 (en) 2013-11-21
AU2013262874A2 (en) 2015-01-22
CA2873485C (en) 2020-05-05
US20160115175A1 (en) 2016-04-28
JP6209209B2 (ja) 2017-10-04
BR112014028221A2 (pt) 2020-10-27
CN104487442A (zh) 2015-04-01
EA034749B1 (ru) 2020-03-17
US20170342085A1 (en) 2017-11-30
AU2019204423A1 (en) 2019-07-11
MX362060B (es) 2019-01-07
SG11201407533SA (en) 2014-12-30
AU2013262874B2 (en) 2017-11-02
CN104487442B (zh) 2016-10-26
JP6408656B2 (ja) 2018-10-17
PL3239153T3 (pl) 2019-09-30
SG10201703451RA (en) 2017-06-29
EP2850085A1 (en) 2015-03-25
EA201790963A1 (ru) 2018-02-28
KR102078233B1 (ko) 2020-02-17
SI3239153T1 (sl) 2019-08-30
AU2017248566A1 (en) 2017-11-09
EP3239153B1 (en) 2019-05-08
PT3239153T (pt) 2019-07-30
ES2738012T3 (es) 2020-01-17
EP2850085B1 (en) 2017-03-15
CN109970749A (zh) 2019-07-05
CN106432254A (zh) 2017-02-22
AU2013262874A1 (en) 2014-12-11
US20140316144A1 (en) 2014-10-23
IL235645A0 (en) 2015-02-01
PT2850085T (pt) 2017-06-26
US20190337960A1 (en) 2019-11-07
EA201492002A1 (ru) 2015-11-30
KR20150008908A (ko) 2015-01-23
SI2850085T1 (sl) 2017-08-31
US10800789B2 (en) 2020-10-13
US20130309196A1 (en) 2013-11-21
MX2014013660A (es) 2015-04-17
US9682989B2 (en) 2017-06-20
HK1245262B (en) 2020-01-10
BR112014028221B1 (pt) 2022-05-03
WO2013173488A1 (en) 2013-11-21
ES2628350T3 (es) 2017-08-02
IN2014MN02459A (h) 2015-07-10
CN106432254B (zh) 2018-12-28
KR20200017557A (ko) 2020-02-18
EP3239153A1 (en) 2017-11-01
JP2015517527A (ja) 2015-06-22
JP2017160276A (ja) 2017-09-14
HK1205126A1 (en) 2015-12-11
EA028026B1 (ru) 2017-09-29

Similar Documents

Publication Publication Date Title
SI2850085T1 (sl) Antivirusne spojine inhibitorjev hcv ns5a
IL269662A (en) Hepatitis C virus inhibitors
EP2575866A4 (en) HCV NS5A INHIBITORS
EP2575475A4 (en) HCV NS5A INHIBITORS
AP3576A (en) Inhibitors of flaviviridae viruses
ZA201409215B (en) Macrocyclic inhibitors of flaviviridae viruses
IL236005A0 (en) Macrocyclic inhibitors of flavoviride viruses
IL236006A0 (en) Macrocyclic inhibitors of flavoviride viruses
IL236004A0 (en) Solid states of an antiviral compound
AP2012006413A0 (en) Inhibitors of flaviviridae viruses
EP2802574A4 (en) INHIBITORS OF HCV NS3 PROTEASE
PL2850075T3 (pl) Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c